At the time of writing, Bristol-Myers Squibb Co [BMY] stock is trading at $56.72, up 4.23%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The BMY shares have gain 4.63% over the last week, with a monthly amount glided 8.76%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Bristol-Myers Squibb Co [NYSE: BMY] stock has seen the most recent analyst activity on January 07, 2026, when UBS upgraded its rating to a Buy but kept the price target unchanged to $65 for it. Previously, BofA Securities upgraded its rating to Buy on December 15, 2025, and kept the price target unchanged to $61. On December 12, 2025, upgrade upgraded it’s rating to Buy but maintained its price target of $62 on the stock. Scotiabank started tracking the stock assigning a Sector Perform rating and suggested a price target of $45 on November 13, 2025. Daiwa Securities downgraded its rating to a Neutral but $42 remained the price target by the analyst firm on August 05, 2025. In a note dated April 22, 2025, Cantor Fitzgerald initiated a Neutral rating and provided a target price of $55 on this stock.
For the past year, the stock price of Bristol-Myers Squibb Co fluctuated between $42.52 and $63.33. Currently, Wall Street analysts expect the stock to reach $53.86 within the next 12 months. Bristol-Myers Squibb Co [NYSE: BMY] shares were valued at $56.72 at the most recent close of the market. An investor can expect a potential drop of -5.04% based on the average BMY price forecast.
Analyzing the BMY fundamentals
According to Bristol-Myers Squibb Co [NYSE:BMY], the company’s sales were 48.03B for trailing twelve months, which represents an -0.97% plunge. Gross Profit Margin for this corporation currently stands at 0.66% with Operating Profit Margin at 0.29%, Pretax Profit Margin comes in at 0.17%, and Net Profit Margin reading is 0.13%. To continue investigating profitability, this company’s Return on Assets is posted at 0.06, Equity is 0.35 and Total Capital is 0.2. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of2.75.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 55.72 points at the first support level, and at 54.72 for the second support level. However, for the 1st resistance point, the stock is sitting at 57.23, and for the 2nd resistance point, it is at 57.74.
Ratios To Look Out For
It is important to note that Bristol-Myers Squibb Co [NYSE:BMY] has a current ratio of 1.27. In addition, the Quick Ratio stands at 1.17 and the Cash Ratio stands at 0.56. Considering the valuation of this stock, the price to sales ratio is 2.40, the price to book ratio is 6.22 and price to earnings (TTM) ratio is 19.15.
Transactions by insiders
Recent insider trading involved Elkins David V, EVP, Chief Financial Officer, that happened on Sep 02 ’25 when 56000.0 shares were sold. Officer, Elkins David V completed a deal on Sep 02 ’25 to buy 56000.0 shares. Meanwhile, EVP, Corporate Affairs Short Bartie Wendy sold 378.0 shares on Aug 02 ’25.
